RESULTS OF MODERN COMPLEX TREATMENT OF PSORIASIS

Abstract

Studies have identified loci of psoriatic predisposition. One specific
marker (Psoriasis susceptibility 1, PSORS 1) is localized on chromosome 6p21, in
the major histocompatibility complex (MHC), which accounts for 30 to 50% of
genetic susceptibility [8,9]. The second psoriasis susceptibility locus (PSORS 2) is
located at 17q24-q25. Other HLA types most often found in psoriasis are HLA -
B13, B17, Bw 57, Cw6. A genome-wide analysis of a study of 1,000 psoriasis
patients identified and confirmed an association between psoriasis and seven
genetic loci - HLA-C, IL12B, IL23R, IL23A, IL4/IL13, TNFAIP3, and TNIP1.
Ongoing research is identifying additional loci [10,11]. Modern understanding of
psoriasis is based on centuries of research. First described the clinic of psoriasis
A.K. Celsus (c. 30 BC - c. 40 AD). Claudius Galen (c. 129 - c. 201), a Roman
physician, first proposed the term "psoriasis" [1,2]. In 1847, Auspitz describes the
symptom of pinpoint bleeding, and in 1876, Koebner's work was published on the
specific reaction of the skin of patients with psoriasis to mechanical trauma. A
significant role in the study of psoriasis belongs to the first Russian professor of
dermatology, Alexei Gerasimovich Polotebnov, who was one of the first to
evaluate psoriasis in connection with visceral pathology, metabolism, and the state
of the nervous system [3]. In the literature, the authors point to the systemic nature
of the pathological process in psoriasis and suggest using the concept of "psoriatic
disease" rather than psoriasis [4,5]. In the scientific literature, the authors at
different times considered various theories of the origin of psoriasis: genetic,
infectious, immunological, metabolic, endocrine, neurogenic, intestinal [6,7].